Home data presented
 

Keywords :   


Tag: data presented

Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

2013-11-15 23:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Mercks investigational anti-PD-1 immunotherapy. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced presented

 

Interim Data for Mercks MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung Cancer

2013-10-01 19:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, confirmed today that interim data from the companys Phase IB expansion study (PN 001) evaluating the efficacy and safety of *MK-3475 in patients with refractory non-small cell lung cancer (NSCLC) is scheduled for presentation at the 15th World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m. EDT), in Sydney, Australia. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: on world data presented

 
 

Data from Mercks Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting

2013-10-01 16:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the companys investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. Language: English Contact: MerckMedia:Sarra Herzog, 908-423-6154orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

 

MolMed ASCO 2013: New data presented on NGR-hTNF

2013-06-07 08:19:10| Logistics - Topix.net

These final results indicate a statistically significant 50% relative reduction in the risk of death.

Tags: data presented asco data presented

 

EpiCept Announces New Crolibulin Data Presented at ASCO 2013 Support...

2013-06-03 07:18:32| Biotech - Topix.net

EpiCept Corporation today announced that new data supporting further evaluation of crolibulin were presented at the Annual Meeting of the American Society of Clinical Oncology , taking place May 31 to June 4, 2013 at the McCormick Place Convention Center in Chicago.

Tags: support data presented announces

 

Sites : [1] [2] [3] [4]